These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6362765)

  • 1. The withdrawal of benztropine mesylate in chronic schizophrenic patients.
    Baker LA; Cheng LY; Amara IB
    Br J Psychiatry; 1983 Dec; 143():584-90. PubMed ID: 6362765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures.
    Gardos G; Cole JO; Rapkin RM; LaBrie RA; Baquelod E; Moore P; Sovner R; Doyle J
    Arch Gen Psychiatry; 1984 Nov; 41(11):1030-5. PubMed ID: 6149737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dose-response relationship for memory impairment by anticholinergic drugs.
    McEvoy JP; Freter S
    Compr Psychiatry; 1989; 30(2):135-8. PubMed ID: 2920548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of the need for anticholinergic medication in patients treated with long-term antipsychotics.
    Caradoc-Davies G; Menkes DB; Clarkson HO; Mullen PE
    Aust N Z J Psychiatry; 1986 Jun; 20(2):225-32. PubMed ID: 2876700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benztropine psychosis.
    Ananth JV; Jain RC
    Can Psychiatr Assoc J; 1973 Oct; 18(5):409-14. PubMed ID: 4746144
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacotherapy of impaired affect in recovering schizophrenic patients.
    Hogarty GE; McEvoy JP; Ulrich RF; DiBarry AL; Bartone P; Cooley S; Hammill K; Carter M; Munetz MR; Perel J
    Arch Gen Psychiatry; 1995 Jan; 52(1):29. PubMed ID: 7811160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of benztropine mesylate and amantadine HCl in neuroleptic-induced extrapyramidal symptoms.
    Stenson RL; Donion PT; Meyer JE
    Compr Psychiatry; 1976; 17(6):763-8. PubMed ID: 791573
    [No Abstract]   [Full Text] [Related]  

  • 8. Ethopropazine and benztropine in neuroleptic-induced parkinsonism.
    Chouinard G; Annable L; Ross-Chouinard A; Kropsky ML
    J Clin Psychiatry; 1979 Mar; 40(3):147-52. PubMed ID: 33969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of amantadine in drug-induced extrapyramidal disorders.
    DiMascio A; Bernardo DL; Greenblatt DJ; Marder JE
    Arch Gen Psychiatry; 1976 May; 33(5):599-602. PubMed ID: 5066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia.
    McEvoy JP; McCue M; Freter S
    Clin Ther; 1987; 9(4):429-33. PubMed ID: 2886223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A quantitative study of neuroleptic-induced extrapyramidal symptoms and their response to dexetimide, a potent and long-acting antiparkinsonian agent.
    Dom R; Van Lommel R; Baro F
    Acta Psychiatr Scand; 1971; 47(4):399-410. PubMed ID: 4947805
    [No Abstract]   [Full Text] [Related]  

  • 12. Extrapyramidal side effects in chlorpromazine recipients: emergence according to benztropine prophylaxis.
    Swett C; Cole JO; Shapiro S; Slone D
    Arch Gen Psychiatry; 1977 Aug; 34(8):942-3. PubMed ID: 889418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biperiden withdrawal in schizophrenic inpatients receiving long-term antipsychotic medication.
    Wada Y; Koshino Y; Yamaguchi N
    Clin Neuropharmacol; 1987 Aug; 10(4):370-5. PubMed ID: 2902920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiparkinsonian agents and depot phenothiazine.
    Chien CP; Dimascio A; Cole JO
    Am J Psychiatry; 1974 Jan; 131(1):86-90. PubMed ID: 4808437
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics and clinical effects of amantadine in drug-induced extrapyramidal symptoms.
    Greenblatt DJ; DiMascio A; Harmatz JS; Bernardo DL; Marder JE
    J Clin Pharmacol; 1977; 17(11-12):704-8. PubMed ID: 336651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protracted vomiting following abrupt cessation of psychotropics: a case report.
    Kalman T; Warner GM
    Can Psychiatr Assoc J; 1978 Apr; 23(3):163-5. PubMed ID: 647615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gradual withdrawal of antiparkinson medication in chronic schizophrenics: any better than the abrupt?
    Manos N; Gkiouzepas J; Tzotzoras T; Tzanetoglou A
    J Nerv Ment Dis; 1981 Oct; 169(10):659-61. PubMed ID: 6116743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative side effects of imipramine, benztropine, or their combination in patients receiving fluphenazine decanoate.
    Siris SG; Rifkin A; Reardon GT; November M
    Am J Psychiatry; 1983 Aug; 140(8):1069-71. PubMed ID: 6346910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiparkinson medication in the treatment of extrapyramidal side effects: single of multiple daily doses?
    Neu C; Dimascio A; Demirgian E
    Curr Ther Res Clin Exp; 1972 May; 14(5):246-51. PubMed ID: 4623975
    [No Abstract]   [Full Text] [Related]  

  • 20. Noncompliance with antiparkinsonian medications in neuroleptic-treated schizophrenic patients: three cases of an unreported phenomenon.
    Bermanzohn PC; Siris SG
    J Clin Psychiatry; 1994 Nov; 55(11):488-91. PubMed ID: 7989282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.